share_log

10-Q/A: Quarterly report (Amendment)

10-Q/A: Quarterly report (Amendment)

10-Q/A：季度報表(修正版)
美股SEC公告 ·  2024/09/24 04:59

Moomoo AI 已提取核心訊息

Revelation Biosciences reported a net loss of $2.7 million for Q1 2024, compared to net earnings of $6.2 million in Q1 2023. Total operating expenses increased to $1.9 million from $1.6 million YoY, with research and development expenses rising to $0.7 million and general and administrative costs reaching $1.2 million. The company ended the quarter with cash and cash equivalents of $14.6 million.The company completed a public offering in February 2024, raising net proceeds of $5.4 million through the issuance of common stock and warrants. The offering included 128,470 shares of common stock and 1,236,530 pre-funded warrants, along with 2,730,000 warrants to purchase common stock at an exercise price of $4.53 per share expiring in February 2029.Management indicated that current cash and cash equivalents balance will not be sufficient to sustain operations within one year, raising substantial doubt about the company's ability to continue as a going concern. The company plans to seek additional funding through public or private equity or debt financings to support its clinical development programs, including GEM-AKI, GEM-CKD, and GEM-SSI.
Revelation Biosciences reported a net loss of $2.7 million for Q1 2024, compared to net earnings of $6.2 million in Q1 2023. Total operating expenses increased to $1.9 million from $1.6 million YoY, with research and development expenses rising to $0.7 million and general and administrative costs reaching $1.2 million. The company ended the quarter with cash and cash equivalents of $14.6 million.The company completed a public offering in February 2024, raising net proceeds of $5.4 million through the issuance of common stock and warrants. The offering included 128,470 shares of common stock and 1,236,530 pre-funded warrants, along with 2,730,000 warrants to purchase common stock at an exercise price of $4.53 per share expiring in February 2029.Management indicated that current cash and cash equivalents balance will not be sufficient to sustain operations within one year, raising substantial doubt about the company's ability to continue as a going concern. The company plans to seek additional funding through public or private equity or debt financings to support its clinical development programs, including GEM-AKI, GEM-CKD, and GEM-SSI.
Revelation Biosciences報告2024年第一季度淨虧損270萬美金，而2023年第一季度淨收益爲620萬美金。總營業費用同比增加至190萬美金，較上一年160萬美金上升，研發費用上升至70萬美金，管理費用達到120萬美金。公司在季度末的現金及現金等價物爲1460萬美金。公司於2024年2月完成了一次公開發行，通過發行普通股和Warrants籌集了淨收益540萬美金。此次發行包括128,470股普通股和1,236,530個預資Warrants，以及2,730,000個以每股4.53美金的行權價購買普通股的Warrants，該Warrants於2029年2月到期。管理層指出，當前的現金及現金等價物餘額不足以在一年內維持運營，令公司繼續作爲一個持續經營實體的能力產生了重大疑慮。公司計劃通過公開或股權投資或債務融資尋求額外資金，以支持其臨牀開發項目，包括GEM-AKI、GEM-CKD和GEM-SSI。
Revelation Biosciences報告2024年第一季度淨虧損270萬美金，而2023年第一季度淨收益爲620萬美金。總營業費用同比增加至190萬美金，較上一年160萬美金上升，研發費用上升至70萬美金，管理費用達到120萬美金。公司在季度末的現金及現金等價物爲1460萬美金。公司於2024年2月完成了一次公開發行，通過發行普通股和Warrants籌集了淨收益540萬美金。此次發行包括128,470股普通股和1,236,530個預資Warrants，以及2,730,000個以每股4.53美金的行權價購買普通股的Warrants，該Warrants於2029年2月到期。管理層指出，當前的現金及現金等價物餘額不足以在一年內維持運營，令公司繼續作爲一個持續經營實體的能力產生了重大疑慮。公司計劃通過公開或股權投資或債務融資尋求額外資金，以支持其臨牀開發項目，包括GEM-AKI、GEM-CKD和GEM-SSI。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Hoth Therapeutics
    HOTH
    -- 1.2400
    Rapport Therapeutics
    RAPP
    -- 9.990
    Protagenic Therapeutics
    PTIX
    -- 0.3681
    Exicure
    XCUR
    -- 14.2800
    Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
    CYCCP
    -- 9.240
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日